GSK3B and cholangiocarcinoma: Interestingly, β-escin increases cholangiocarcinoma cells line sensitivity to chemotherapy, by inducing GSK-3β phosphorylation and dephosphorylation at tyrosine-216 and serine-9, respectively, leading to β-catenin degradation [55].